Skip to main content

Advertisement

Table 4 Changes in LMR and benefits of chemotherapy

From: Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Pre- and post-chemotherapy LMR No. of patients Progression-free survival (months) Overall survival (months)
Median (95% CI) HR (95% CI) P value Median (95% CI) HR (95% CI) P value*
Low–low 87 5.8 (5.1–6.5) 1   13.0 (10.3–15.7) 1  
Low–high 129 8.4 (7.7–9.1) 0.524 (0.391–0.702) <0.001 17.8 (16.9–18.7) 0.522 (0.371–0.771) <0.001
High–low 151 8.2 (7.8–8.6) 0.733 (0.636–0.846) <0.001 17.0 (15.6–18.4) 0.837 (0.699–1.003) 0.053
High–high 121 10.6 (9.8–11.4) 0.631 (0.566–0.702) <0.001 22.2 (21.0–23.4) 0.636 (0.562–0.719) <0.001
  1. Abbreviations as in Tables 1 and 2
  2. *Tested by COX proportional hazards model in which the reference is the low–low group, and adjusted with the ECOG performance status, number of metastatic sites, and differentiation